About Royalty Pharma plc
https://www.royaltypharma.comRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
CEO
Pablo Gerardo Legorreta
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 563
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:44.16M
Value:$1.78B
FMR LLC
Shares:27.99M
Value:$1.13B
CAPITAL INTERNATIONAL INVESTORS
Shares:27.21M
Value:$1.09B
Summary
Showing Top 3 of 544
About Royalty Pharma plc
https://www.royaltypharma.comRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $609.29M ▲ | $182.13M ▼ | $288.22M ▲ | 47.3% ▲ | $0.67 ▲ | $525.05M ▲ |
| Q2-2025 | $578.66M ▲ | $368.87M ▲ | $30.18M ▼ | 5.21% ▼ | $0.07 ▼ | $159.3M ▼ |
| Q1-2025 | $568.25M ▼ | $34.06M ▼ | $238.35M ▲ | 41.94% ▲ | $0.55 ▲ | $498.69M ▲ |
| Q4-2024 | $593.64M ▲ | $232.13M ▲ | $208.21M ▼ | 35.07% ▼ | $0.47 ▼ | $400.11M ▼ |
| Q3-2024 | $564.69M | $-170.38M | $543.99M | 96.33% | $1.22 | $872.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $955.04M ▼ | $19.35B ▲ | $9.73B ▲ | $6.41B ▲ |
| Q2-2025 | $1.49B ▼ | $18.32B ▲ | $8.82B ▲ | $6.35B ▼ |
| Q1-2025 | $1.82B ▲ | $17.61B ▼ | $7.82B ▼ | $6.69B ▼ |
| Q4-2024 | $1.77B ▲ | $18.22B ▲ | $7.88B ▲ | $6.95B ▲ |
| Q3-2024 | $1.76B | $18.04B | $7.78B | $6.87B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-463.61M ▼ | $639.63M ▲ | $-900.15M ▼ | $567.56M ▲ | $307.04M ▲ | $640.74M ▲ |
| Q2-2025 | $30.18M ▼ | $426.97M ▼ | $-370.15M ▼ | $-512.64M ▲ | $-455.81M ▼ | $426.97M ▼ |
| Q1-2025 | $433.43M ▲ | $596.08M ▼ | $503.92M ▲ | $-941.3M ▼ | $158.69M ▲ | $596.08M ▼ |
| Q4-2024 | $334.35M ▼ | $742.52M ▲ | $-505.59M ▲ | $-257.96M ▲ | $-21.03M ▲ | $742.52M ▲ |
| Q3-2024 | $806.36M | $703.61M | $-1.19B | $-325.5M | $-814.59M | $703.61M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Financial Royalty Assets | $1.07Bn ▲ | $540.00M ▼ | $550.00M ▲ | $580.00M ▲ |
 Royalty Income Other | $60.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
CEO
Pablo Gerardo Legorreta
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 563
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:44.16M
Value:$1.78B
FMR LLC
Shares:27.99M
Value:$1.13B
CAPITAL INTERNATIONAL INVESTORS
Shares:27.21M
Value:$1.09B
Summary
Showing Top 3 of 544